Tecan Group AG focuses on life science automation. Long-term growth story for laboratory technology
Published on 07/06/2026 at 10:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Tecan Group AG (ISIN CH0012100191) is a Switzerland-based supplier of laboratory instruments and automation solutions that supports customers in clinical diagnostics and life science research with modular platforms and consumables.
The company specializes in automating sample handling and analytical workflows, enabling laboratories to increase throughput, improve reproducibility, and optimize the use of skilled personnel.
Laboratory automation as core business
Tecan Group AG generates most of its business by designing and manufacturing automated instruments that handle pipetting, liquid handling, and sample preparation in routine and research laboratories.
Customers use these systems to standardize complex protocols, reduce manual steps, and support the reliable execution of diagnostic tests and research assays across large batches of samples.
Diagnostics and research customer base
The company serves a broad base of customers that includes clinical laboratories, diagnostics providers, pharmaceutical and biotechnology companies, and academic research institutions that require reliable, scalable automation.
Through its portfolio of instruments, consumables, and services, Tecan aims to provide integrated workflow solutions that can be adapted to specific applications in areas such as molecular diagnostics, immunoassays, and drug discovery.
Representative product platform
One representative example of Tecan's offering is its family of automated liquid handling workstations, which are designed to support a range of applications by combining configurable hardware with software that manages complex laboratory workflows.
Tecan stock and listing
Tecan Group AG is listed on the Swiss market, where its shares provide investors with exposure to the global laboratory automation and diagnostics equipment segment.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
